Novo Nordisk Shares Navigate a Week of Market Turbulence

Investors in Novo Nordisk experienced significant volatility this past week, buffeted by contrasting developments across clinical trials and regulatory landscapes. The Danish pharmaceutical giant faced a disappointing clinical setback, received encouraging pipeline news, and witnessed a favorable shift in U.S. pricing regulations, creating a rollercoaster for its stock.

The most impactful shift occurred on Thursday. Market sentiment improved considerably following reports that potential U.S. government price negotiations for the top-selling drugs Ozempic and Wegovy would be less severe than initially feared. For months, the looming threat of significant price reductions under the Inflation Reduction Act had pressured the company’s valuation, with investors worried about Read more...